Boston, MA – As the world continues to grapple with the COVID-19 pandemic, individuals living with chronic health conditions such as Multiple Sclerosis (MS) have been particularly concerned about their risk and the impact of the disease on their treatments.
MS is a chronic condition in which the immune system attacks the protective myelin layer covering the nerves, affecting processes like sensation, movement, and vision. According to experts, approximately 2.8 million people worldwide, or around 35.9 people for every 100,000, were living with MS in 2020.
For individuals with MS, the symptoms can vary in severity, impacting their daily lives and potentially leading to significant disability. Given the challenges posed by the ongoing pandemic, it’s natural for those with MS to have questions about their risk, treatment, and the safety and efficacy of COVID-19 vaccines.
Research has shown that individuals with MS do not seem to have a higher risk of developing COVID-19, but they may have additional risk factors such as age, medical treatments, or disability that could increase their likelihood of a more severe outcome if they contract the virus. This insight comes from various studies, including one that found a slightly lower incidence of COVID-19 among individuals with MS compared to the general population.
Concerns have been raised about certain MS medications potentially increasing the risk of severe COVID-19. Medications like ocrelizumab and rituximab were identified in studies as potentially heightening the risk of severe COVID-19, prompting the need for individuals to discuss their treatment plans with their healthcare provider.
The National MS Society encourages individuals with MS to receive the COVID-19 vaccine, emphasizing that the benefits of vaccination outweigh any potential risks associated with the disease. However, for those on specific DMTs, it’s important to discuss the timing of vaccinations with their healthcare provider to maximize effectiveness.
Furthermore, a study revealed that individuals with MS may be more likely to experience a slower recovery and be more prone to long COVID symptoms, particularly fatigue. This underscores the importance of staying informed about potential symptoms and seeking assistance from healthcare professionals when necessary.
Despite the challenges, there are measures individuals with MS can take to protect themselves, including getting vaccinated, practicing good hygiene, and discussing their treatment plans with healthcare providers to ensure the best possible outcomes. By staying informed and proactive, individuals with MS can navigate the complexities of the pandemic and continue to prioritize their health and well-being.